TTRX · Turn Therapeutics Inc. · Insider Trading

The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.

The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.

The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.

The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.

This transaction involved the reporting person's gift of 300,000 shares of common stock to the Bradley E. Burnam 2026 Revocable Trust FBO Luca M. Burnam (the "LMB Trust"). The sole beneficiary of the LMB Trust is the reporting person's son. The reporting person disclaims beneficial ownership of the securities held by the LMB Trust, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

This transaction involved the reporting person's gift of 300,000 shares of common stock to the Bradley E. Burnam 2026 Revocable Trust FBO Gabriella G. Burnam (the "GGB Trust"). The sole beneficiary of the GGB Trust is the reporting person's daughter. The reporting person disclaims beneficial ownership of the securities held by the GGB Trust, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Represents shares of common stock held by BEB Holdings, LLC. The reporting person is the sole member of BEB Holdings, LLC and has sole voting and dispositive power with regard to the shares held by BEB Holdings, LLC. Accordingly, all shares held by BEB Holdings, LLC may be deemed to be beneficially owned by the reporting person.

Represents shares of common stock held by BEB Holdings, LLC. The reporting person is the sole member of BEB Holdings, LLC and has sole voting and dispositive power with regard to the shares held by BEB Holdings, LLC. Accordingly, all shares held by BEB Holdings, LLC may be deemed to be beneficially owned by the reporting person.

Represents shares of common stock held by BEB Holdings, LLC. The reporting person is the sole member of BEB Holdings, LLC and has sole voting and dispositive power with regard to the shares held by BEB Holdings, LLC. Accordingly, all shares held by BEB Holdings, LLC may be deemed to be beneficially owned by the reporting person.

The option will vest as follows: 25% will vest on the first anniversary of the grant date, with the remaining 75% vesting ratably over the following 36 months, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.

The option will vest as follows: 25% will vest on the first anniversary of the grant date, with the remaining 75% vesting ratably over the following 36 months, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.

The securities reported in Column 5 of Table I are restricted stock units ("RSU"). Each RSU represents a contingent right to receive one share of common stock, subject to the applicable vesting schedule and conditions of the applicable RSU award and the Issuer's 2025 Omnibus Incentive Plan. The 21,882 RSUs included in Column 5 of Table I vest in full on January 7, 2027, subject to the reporting person's continuous service to the Issuer.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.50, inclusive. The Reporting Person undertakes to provide to Turn Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Certain of the securities reported in Column 5 of Table I are restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and the reporting person's continuous service through the vesting date.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.66 to $3.25, inclusive. The Reporting Person undertakes to provide to Turn Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Certain of the securities reported in Column 5 of Table I are restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and the reporting person's continuous service through the vesting date.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.69, inclusive. The Reporting Person undertakes to provide to Turn Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Certain of the securities reported in Column 5 of Table I are restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and the reporting person's continuous service through the vesting date.

Shares are held indirectly through ANC Merchant FLP and ANC Carlson FLP, each owned 48% by the reporting person, 48% by the reporting person's spouse, and 2% by each of the reporting person's two children; the reporting person disclaims beneficial ownership of the shares attributable to his spouse except to the extent of his pecuniary interest therein.

Reflects an award of restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. These RSUs will vest upon the earlier of the first anniversary of the grant date or a change in control of the Issuer, in each case, subject to the reporting person's continuous service through the vesting date.

Reflects an award of restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. These RSUs will vest upon the earlier of the first anniversary of the grant date or a change in control of the Issuer, in each case, subject to the reporting person's continuous service through the vesting date.

Reflects an award of restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. These RSUs will vest upon the earlier of the first anniversary of the grant date or a change in control of the Issuer, in each case, subject to the reporting person's continuous service through the vesting date.

Reflects an award of restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. These RSUs will vest upon the earlier of the first anniversary of the grant date or a change in control of the Issuer, in each case, subject to the reporting person's continuous service through the vesting date.

Reflects an award of stock options to purchase shares of the Issuer's common stock granted under the Company's 2025 Omnibus Incentive Plan. 25% of the options shall vest on May 1, 2026, and 6.25% of the options shall vest in equal quarterly installments thereafter, in each case, subject to the reporting person's continued employment through the applicable vesting date.